Next Article in Journal
Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients
Previous Article in Journal
Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Cancers 2019, 11(3), 281; https://doi.org/10.3390/cancers11030281

Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model

1
Ph.D. program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 110, Taiwan
2
Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 115, Taiwan
3
Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan
4
Institute of Chemistry, Academia Sinica, Taipei 115, Taiwan
*
Author to whom correspondence should be addressed.
Received: 26 January 2019 / Revised: 21 February 2019 / Accepted: 22 February 2019 / Published: 27 February 2019
Full-Text   |   PDF [3987 KB, uploaded 28 February 2019]   |  
  |   Review Reports

Abstract

Colorectal cancer (CRC) is the most frequently diagnosed cancer and leading cause of cancer-related deaths worldwide. Because of the use of first-line CRC treatments, such as irinotecan (IRI), is hindered by dose-limiting side effects, improved drug delivery systems may have major clinical benefits for CRC treatment. In this study, we generate and characterize liposomal irinotecan (Lipo-IRI), a lipid-based nanoparticle, which shows excellent bioavailability and pharmacokinetics. Additionally, this formulation allows IRI to be maintained in active form and prolongs its half-life in circulation compared to IRI in solution. Compared with IRI statistically, the level of prostaglandin E2 (PGE2) in colonic tissue decreases, and Bifidobacterium spp. (beneficial intestinal microbiota) content increases in the Lipo-IRI-treated group. Moreover, no damage is observed by the hematoxylin and eosin staining of the normal tissue samples from the Lipo-IRI-treated group. In a xenograft mouse model, CRC tumors shrink markedly following Lipo-IRI treatment, and mice receiving a targeted combination of Lipo-IRI and liposomal doxorubicin (Lipo-Dox) extend their survival rate significantly. Overall, our results demonstrate that this formulation of Lipo-IRI shows a great potential for the treatment of colorectal cancer. View Full-Text
Keywords: colorectal cancer; liposomal irinotecan; combination targeted therapy; drug delivery system; microbiota colorectal cancer; liposomal irinotecan; combination targeted therapy; drug delivery system; microbiota
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Huang, J.-R.; Lee, M.-H.; Li, W.-S.; Wu, H.-C. Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model. Cancers 2019, 11, 281.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top